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Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder in children, with
worldwide prevalence of ADHD varying from 5.9 to 7.1 %, depending on the reporter. In case of inadequate response
to stimulants, combination therapy of stimulants and an adjunctive medication may improve the control of ADHD
symptoms, reduce the dose-limiting adverse events, and help control comorbidities. To date, the only medication to
be used for adjunctive therapy to psychostimulants is guanfacine extended release (GXR). The aim of this study was to
assess the economic impact of GXR as an adjunct therapy with long-acting stimulants (GXR + stimulant) compared to
long-acting stimulant monotherapy (stimulant alone) in the treatment of children and adolescents with ADHD in
Canada.
Method: A Markov model was developed using health states defined based on the clinician-reported Clinical Global
Impression-Severity (CGI-S) score (normal, mild, moderate, severe). Transition probabilities were calculated based on
patient-level data from a published study. Long-acting stimulants available in Canada were considered in the base-case
model: amphetamine mixed salts, methylphenidate HCl formulations, and lisdexamfetamine dimesylate. Analyses were
conducted from a Canadian Ministry of Health (MoH; Ontario) and a societal perspective over a 1-year time horizon
with weekly cycles.
Results: Over a 1-year time horizon, GXR + stimulant was associated with 0.655 quality-adjusted life year (QALY),
compared to 0.627 QALY with stimulant alone, for a gain of 0.028 QALY. From a MoH perspective, GXR+ stimulant and
stimulant alone were associated with total costs of $CA1,617 and $CA949, respectively (difference of $CA668), which
resulted in an incremental cost-effectiveness ratio (ICER) of $CA23,720/QALY. From a societal perspective, GXR + stimulant
and stimulant alone were associated with total costs of $CA3,915 and $CA3,582, respectively (difference of $CA334),
which resulted in an ICER of $CA11,845/QALY. Probabilistic sensitivity analysis (PSA) of GXR + stimulant showed that it
remains a cost-effective strategy in 100 % of the simulations from both perspectives in numerous PSA and one-way
sensitivity analyses, relative to a willingness to pay threshold of $50,000/QALY.
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Conclusions: This economic evaluation demonstrates that GXR + stimulant is cost-effective compared to stimulant alone
in the treatment of children and adolescents with ADHD in Canada.
Keywords: Attention-deficit/hyperactivity disorder, Guanfacine extended-release, Stimulants, Adjunctive therapy,
Pediatrics, Canada, Cost-effectiveness, Cost-utility
Background
Attention-deficit hyperactivity disorder (ADHD) is among
the most common psychiatric disorder in children, with
an overall Canadian prevalence in children that has in-
creased from 1.3 % in 1994–1995 to 2.1 % in 2008–2009
[1]. The worldwide prevalence of ADHD varying from 5.9
to 7.1 %, depending on the reporter [2]. As ADHD is asso-
ciated with a substantial clinical burden, it imposes a
significant economic impact on the health care system
and society. In fact, ADHD is associated with an increased
risk of substance use, a lower academic performance and
occupational status, absenteeism, and productivity loss
[3–5]. According to the Centre for ADHD Awareness,
Canada, the total economic burden associated with
ADHD in children would reach $CA2 billion per year
based on US cost estimates [6]. More recently, a sys-
tematic review by Doshi et al. indicated that the overall
annual incremental costs of ADHD in the US ranged
from $US143 to $US266 billion, of which between
$US38 and $US72 billion were incurred by children
and adolescents [7].
The availability of effective ADHD treatments may
contribute to reduce the substantial psychosocial and
economic burden of the disorder. According to recent
Canadian guidelines, long-acting stimulants are recom-
mended as the first-line treatment of ADHD in children
aged from 6 to 12 years [8]. However, approximately 30 %
of children with ADHD do not have an adequate response
to a single stimulant, often defined as a percentage im-
provement on the ADHD Rating Scale IV (ADHD-RS-IV)
or change in Clinical Global Impression-Improvement
score [9, 10]. However, for many reasons, such as having
an inadequate or partial response and dose-limiting side
effects, some patients with ADHD augment their existing
stimulant with additional medications [11, 12]. A recent
Canadian study found that children and adolescents with
ADHD treated with stimulants in Quebec had rates of
adjunctive therapy of 19.8 and 18.7 %, respectively [13]. A
combination therapy comprising multiple stimulants
(treatments initially given together) and an adjunctive
medication (a second treatment added to the initial treat-
ment) may improve the control of core ADHD symptoms,
reduce the dose-limiting adverse events (AEs) associated
with stimulants, and help control comorbidities (including
mood, anxiety, and substance disorders) [9]. In a Canadian
retrospective claims analysis, approximately one in five
children/adolescents with ADHD were on a stimulant ex-
perienced combination therapy [14]. Despite the relatively
high prevalence of adjunctive therapy among stimulant
users, there are limited clinical trial data to support the
use of a stimulant and another medication as adjunctive
therapy.
To date, in Canada, the only medication approved by
Health Canada for adjunctive therapy to stimulants in
children aged 6–12 years is Intuniv XR™ (guanfacine
extended release [GXR]; Shire Canada Inc., Saint-Laurent,
QC, Canada). The efficacy and tolerability of GXR as an
adjuctive therapy has been demonstrated in randomized
placebo controlled clinical trials [15, 16]. In these studies,
GXR treatment groups showed significantly greater symp-
tom reduction from baseline as measured by the ADHD-
RS-IV total score compared to placebo plus stimulant at
endpoint.
GXR as an adjunctive therapy to existing simulant
monotherapy has been shown to be cost-effective com-
pared to existing stimulant monotherapy alone in a US
context [17]. However, the cost-effectiveness of GXR as an
adjunctive therapy for the treatment of ADHD has not
been evaluated in Canada. Therefore, the aim of this study
was to perform a cost-effectiveness analysis (CEA) com-
paring GXR as an adjunctive therapy to stimulants with
stimulant monotherapy among children with ADHD who
had a suboptimal response to stimulants in a Canadian
economic context.
Methods
A CEA was performed to assess the economic impact of
GXR as an adjunctive therapy to long-acting stimulants
in the treatment of ADHD. This economic evaluation
was based on the recently published results from a ran-
domized study by Wilens et al., which compared GXR as
an adjunctive therapy to stimulants with placebo plus
stimulants (no distinction between stimulants) [16]. It
was assumed that the target population, treatment effi-
cacy, and tolerability profile used in the US clinical trial
was generalizable to a similar ADHD target population
in Canada.
Comparative treatment
According to Canadian ADHD treatment guidelines, long-
acting stimulants are the mainstays of pharmacological
therapy and are first-line treatment options for the majority
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of patients with ADHD [8]. Specifically, Adderall XR®
(amphetamine mixed salts [MAS-XR]; Shire Canada Inc.),
Concerta® (methylphenidate HCl extended release [OROS-
MPH]; Janssen Inc., Toronto, ON, Canada) and generic,
Biphentin® (methylphenidate HCl controlled release [MPH-
CR]; Purdue Pharma, Pickering, ON, Canada) and Vyvanse®
(lisdexamfetamine dimesylate [LDX]; Shire Canada Inc.) are
available in Canada for the treatment of ADHD [18, 19]. In
case of suboptimal response to long-acting stimulants, an
adjunctive medication can be added. Therefore, in the
base-case analysis of this CEA, GXR as an adjunctive ther-
apy to a long-acting stimulant was compared to long-acting
stimulant monotherapy.
In the pivotal US study, GXR or placebo was co-
administered to a long-acting stimulant in patients who
had a suboptimal response to stimulants alone [16]. Sub-
optimal response was defined as follows: ≥4 weeks of a
stable dose of treatment with an extended-release stimulant
with improvement but continued mild to moderate symp-
toms of ADHD; ADHD-RS-IV total score of ≥24 and a
Clinical Global Impression-Severity (CGI-S) score indicative
of at least mild impairment (≥3); and investigator assess-
ment of inadequate response to current stimulant. To rep-
resent the Canadian situation, only long-acting stimulants
available in Canada were considered in the base-case
model: MAS-XR, OROS-MPH, MPH-CR and LDX [8]. As
Biphentin®, a methylphenidate-based stimulant, is not avail-
able in the US and was not assessed in the study by Wilen
et al., a similar efficacy for Biphentin® and other methylphe-
nidates included in the pivotal study was assumed, as sup-
ported by literature [20].
Target population
The study population in the economic evaluation consisted
of children with ADHD aged 6–12 years with a suboptimal
response to stimulants, according to the product label
indication in Canada for GXR. However, in the study by
Wilens et al., the target population was children and
adolescents aged 6–17 years [16]. Within the Wilens
et al. study, changes in ADHD-RS-IV mean total score
from baseline to endpoint were similar between age
groups (6–12 and 13–17 years old) and no efficacy data
were stratified by the child versus adolescent age
groups. In the model, it was assumed that the clinical
efficacy of GXR was similar to that measured in Wilens
et al. The mean age of the trial population was
10.8 years (79.3 % aged 6–12 years; 20.7 % aged 13–17
years) and the proportion of male patients was 71.6 %.
Model structure
A two-stage Markov model was developed over a 1-year
time horizon with weekly cycles, which is in line with
other CEAs of ADHD treatments [21–24]. Markov health
states were defined based on the clinician reported CGI-S
scores and included the following stages of the disease:
severe (CGI-S score of “Severely ill” or “Among the most
extremely ill subjects”), moderate (CGI-S score of “Moder-
ately ill” or “Markedly ill”), mild (CGI-S score of “Border-
line ill” or “Mildly ill”) and normal (CGI-S score of
“Normal”) (Fig. 1). Patients’ starting health state was based
on the distribution of starting CGI-S scores in the trial
across the treatment arms (Table 1).
Consistent with the trial period, the first stage of the
model was assumed to span from week 0 to week 8, and
the second stage extended from week 9 to week 52. All pa-
tients remained on treatment during the first stage of the
model. Thereafter, patients in the moderate or severe states
at week 8 were considered to be non-responsive and there-
fore permanently discontinued their treatments. As most of
the patients included in the trial had moderate or severe
disease at baseline, remaining with a moderate or severe
disease after 8 weeks would indicate a lack of response to
treatment. Similarly, patients who transitioned into the
moderate or severe state during the second stage of the
simulation (weeks 9–52) discontinued treatment and
remained in the last observed health state for the rest of the
model period. In a sensitivity analysis, patients were main-
tained on treatment and could transition between heath
states during the weeks 9–52 period.
Transition probabilities
The transition probabilities between health states
were taken from the patient-level data from the piv-
otal study, as previously described [7]. Briefly, follow-
ing the trial definition of endpoint, the efficacy data
from the first 8 weeks were used. Patients were
assigned each week to one of the four health states




Fig. 1 Diagram of health states. Patients may enter the model in the
mild, moderate, or severe states. Adapted from Sikirika et al. 2012
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In the base-case model, ordered logit models were
used to estimate the transition probabilities, where the
dependent variable was the current health state and the
independent variable was the health state in the previous
week (Table 2). Transition probabilities were estimated
for the placebo plus psychostimulants arm and the com-
bined GXR plus psychostimulants arm for morning and
evening administration. The estimated transition prob-
abilities were applied throughout the model period for
patients remaining on treatment (e.g. 9–52 weeks).
Table 1 Key Model Inputs
Parameter Value Source
Initial health distribution:










Normal $4.71 Derived from Guevara et al. [25], Schedule of




Weekly costs associated with productivity
losses for parents of children with ADHD
(societal perspective):




Daily cost of ADHD medication, $CA:
GXR $3.89 Quebec’s Medication List
MAS-XR (Adderall XR®) $3.24
MPH-CR (Biphentin®) $1.77 ODB
OROS-MPH (Concerta®) $2.76 Market shares – Canada
OROS-MPH (generic) $1.91 (except Quebec), IMS Brogan
LDX (Vyvanse®) $3.75
Long-acting stimulants - Overall $2.80 Weighted average cost
Percentage of patients taking
long-acting stimulants:
GXR – Market shares – Canada (except Quebec),
IMS Brogan
MAS-XR (Adderall XR®) 14.20 %
MPH-CR (Biphentin®) 15.30 %
OROS-MPH (Concerta®) 46.10 %
OROS-MPH (generic) 6.40 %
LDX (Vyvanse®) 18.00 %
ADHD attention-deficit/hyperactivity disorder, GXR guanfacine extended release, LDX lisdexamfetamine dimesylate, MAS-XR mixed amphetamine salts extended
release, MPH-CR methylphenidate hydrochloride controlled release, OCCI Ontatio Case Costing Initiative, ODB Ontario Drug Benefit Formulary, OHIP Ontario Health
Insurance Plan, OROS-MPH osmotic release oral system methylphenidate
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Cost data
All analyses were performed from a Canadian Ministry of
Health (MoH; Ontario) and a societal perspective. All
costs are expressed in 2013 Canadian dollars. Costs esti-
mated before 2013 were adjusted to April 2013 levels
based on the health component of the Canadian Con-
sumer Price Index. No costs were discounted because the
time horizon of this economic evaluation did not exceed
1 year.
The costs included in the analysis from a MoH perspec-
tive were those associated with medication and health care
resources used in the management of ADHD. The unit
cost of GXR for each available dose was taken from the
Quebec’s Medication List, while the daily cost of each
long-acting stimulant was based on daily dose and num-
ber of pills according to Canadian data from IMS Brogan
for children aged 0–12 years [18]. To date, only the prov-
ince of Quebec has approved GXR for reimbursement.
The approval process for reimbursement in other prov-
inces, including Ontario, was pending at the time of the
manuscript. The unit cost of each dose of long-acting
stimulant was taken from the Ontario Drug Benefit For-
mulary [19]. The weighted average cost for each stimulant
was estimated based on the Canadian market shares for
each dose available for the year 2012 provided by IMS
Brogan (Table 1).
Costs associated with health care resources used in the
management of ADHD were based on a study by Guevara
et al. [25]. In this study, resource utilization of specific cat-
egories of health care services including primary care visits,
mental health visits, pharmacy fills, emergency department
visits and hospitalizations were estimated for children with
and without ADHD. Unit costs from Canadian sources
were applied to the additional resource use estimates asso-
ciated with ADHD (resource use for children with ADHD
– resource use for children without ADHD) to obtain the
cost associated with each category of health care service
[26, 27]. The mean cost of a script in Canada was obtained
from IMS Health Canada and was a weighted average of
the mean cost per script of brand and generic products
[28]. The same number of non-ADHD pharmacy fills was
applied to all patients.
Medical costs derived from the study by Guevara et al.
were allocated according to disease severity. More spe-
cifically, the annual medical costs for patients in the
“normal” health state were assumed to be the same as
the median medical costs for non-ADHD patients
($CA245). The cost of the “mild” subgroup has been es-
timated as follows: the annual cost of the 50th patients
(out of 100) with ADHD is $CA322 (median cost) and
the minimal cost for an ADHD patient is $CA245 (cost
without ADHD). Assuming a linear distribution, the
annual cost of the 3.52th patient (the initial proportion
of patients in the “mild” state was 3.52 %) was estimated
at $CA250. Thus, the average cost for the “mild” sub-
group was $CA248 (mean of $CA245 and $CA250). To
properly represent the skewedness of the data, the costs
incurred by the “severe” patients were assumed to be
two times the mean cost estimated from Guevara et al.
($CA738). Therefore, the annual cost in the “severe”
group was estimated at $CA1,476. The average annual
cost in the “moderate” subgroup was then calculated
using the cost estimates of the “mild” and “severe” states
and to retrieve the original mean cost estimated from
Guevara et al. according to the initial distribution of
patients. Therefore the mean annual cost incurred by
the “moderate” state was estimated at $CA709 [16, 25].
The costs of productivity loss associated with ADHD
were added from a societal perspective. These costs were
estimated by a literature review of published productivity
loss data. As no Canadian study was retrieved, product-
ivity loss-related data expressed in number of hours or
days were preferred. Hakkart van Roijen et al. reported
that the mean number of days absent from work per
year was over 17 days for parents of ADHD children in
the Netherlands [29]. This number of days was applied
on a weekly basis, based on the average Canadian
national hourly wage in January 2013 ($CA23.50) [30].
In order to estimate productivity losses associated with
ADHD disease severity, the same ratios calculated for
medical costs were applied to the weekly cost associated
with productivity losses.
Utility
Utility values associated with the model’s health states were
taken from a study by Lloyd et al. [31]. In this study, a
survey was carried out among 100 members of the general
population in the United Kingdom in order to estimate
utility values associated with ADHD-related health states.
Utility values estimated from the time trade-off method
Table 2 Transition probabilities based on logit model
CGI-S health
states
CGI-S health states in Subsequent Week
Normal Mild Moderate Severe
Stimulants only (mean SE)
Normal 0.759 (0.056) 0.238 (0.055) 0.003 (0.001) 0.000 (0.000)
Mild 0.081 (0.013) 0.826 (0.017) 0.093 (0.014) 0.000 (0.000)
Moderate 0.002 (0.001) 0.192 (0.015) 0.801 (0.015) 0.004 (0.003)
Severe 0.000 (0.000) 0.000 (0.000) 0.236 (0.068) 0.763 (0.068)
Combined GXR + stimulants (mean SE)
Normal 0.766 (0.041) 0.231 (0.041) 0.003 (0.001) 0.000 (0.000)
Mild 0.112 (0.014) 0.817 (0.016) 0.070 (0.011) 0.000 (0.000)
Moderate 0.003 (0.001) 0.258 (0.019) 0.737 (0.019) 0.003 (0.001)
Severe 0.000 (0.000) 0.000 (0.000) 0.361 (0.102) 0.550 (0.102)
CGI-S Clinical Global Impression-Severity, GXR guanfacine extended release,
SE standard error
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were used (Table 1). The different ADHD-related
health states found in this study were based on the
CGI-S and were defined similarly to the ones used in
the present model, with the exception that the severe
state excluded CGI-S 7 (“among the most extremely
ill patients”), because no data were available for this
CGI-S score in Lloyd et al. [31].
Adverse events
AEs included in the product monograph that impacted
at least 5 % of all treatment arms were considered. In
the base-case analysis, AEs were assumed to result in a
utility decrement lasting for 4 weeks. Disutilities associ-
ated with AEs were assigned after conducting a literature
review of published utility scores associated with ADHD
treatment-related AEs. The incidences of AEs for both
treatment arms and disutilities associated with AEs were
published previously [17].
Incremental cost-effectiveness analyses
Effectiveness outcomes included average quality-adjusted
life years (QALYs), response rate, number needed to treat
(NNT) and patient-weeks with a response. The incremental
QALYs were calculated as the difference in the average
QALYs over the time horizon between the two compara-
tors. Similarly, the incremental response rate was calculated
as the difference in response rate for GXR with stimulants
at week 8 and response rate for stimulants alone at week 8.
The NNT was calculated as 1/(response rate for GXR – re-
sponse rate for stimulants alone). The incremental patient-
week with a response was calculated as the difference in
the cumulative fraction of patients in either a mild or mod-
erate state over the 52-week period for the two compara-
tors. The incremental cost-effectiveness ratios (ICERs) were
calculated by dividing the difference in total costs of the
GXR + stimulant arm and the stimulant monotherapy arm
by the difference in effectiveness outcomes between both
treatment arms. The incremental cost per patient-week
with a response was taken by dividing the incremental cost
by the incremental patient-weeks with a response.
Source of data
Data used to perform this economic evaluation were taken
from different sources. Data freely available comprised
cost of medications taken from provincial (Quebec and
Ontario) drug formularies, cost associated with medical
management of ADHD and other medical costs taken
from published literature as well as utilities estimates.
Data that were not freely available comprised patient-level
data from the pivotal study to estimate the transition
probabilities and data on market shares and cost per
script. These data were obtained from Shire and IMS
Brogan respectively.
Sensitivity analyses
To confirm the robustness of the base-case results, several
one-way sensitivity analyses were performed by varying a
single variable individually within lower and upper bounds
of all key parameters including: transition probabilities,
costs, utilities, duration of AEs, stimulant choice, and
initial state distribution. More specifically, sensitivity ana-
lysis on transition probabilities were performed using the
observed transitions between the health states during the
first 8 weeks and assuming that health states were stabi-
lized without further transitions in the second stage of the
model (i.e., week 9 to week 52).
In the base-case model, ordered logit models were
used to estimate the transition probabilities. A last ob-
servation carried forward (LOCF) technique was used in
sensitivity analysis to obtain transition probabilities. The
LOCF technique was applied when data were missing
from a particular timeslot, but existed before that slot.
This technique creates efficacy records for missing visits
by carrying data from previous visits forward. One ex-
ception was that observations from the baseline timeslot
were never carried forward into the treatment phase
timeslots.
In most Canadian provinces, long-acting stimulants
are listed on the Drug Benefit Formulary [32]. However,
their coverage is often provided under specific condi-
tions and patients have to meet several criteria, which
may greatly limit the access to long-acting stimulants.
To take this situation into account, a sensitivity analysis
comparing GXR adjunctive therapy to short/intermedi-
ate-acting stimulants with placebo plus short/intermedi-
ate-acting stimulants was performed by varying only the
stimulant drug costs.
In addition, a probabilistic sensitivity analysis (PSA) was
performed to assess the overall impact of uncertainty
associated with study parameters. Simultaneous variations
in all key parameters were performed using Monte Carlo
simulation. A total of 10,000 Monte Carlo simulations
were performed using appropriate distributions (beta dis-
tribution bounded by 0 and 1 for transition probabilities
and utilities, triangular distribution for costs, and uniform
distribution for the duration of all AEs). Results of the
PSA were presented as cost-effectiveness acceptability
curves and the probability of being cost-effective at a
threshold of $50,000/QALY was estimated, which is a
commonly cited threshold by Canadian agencies for
health technology assessment [33].
Results
Base-case analysis
Over a 1-year time horizon, GXR as an adjunctive therapy
to long-acting stimulants was associated with an average
of 0.655 QALYs, compared to an average of 0.627 QALY
with long-acting stimulants as monotherapy, for a gain of
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0.028 QALY (Table 3). From a MoH perspective, GXR as
an adjunctive therapy to long-acting stimulants and long-
acting stimulants as monotherapy were associated with
total costs of $CA1,617 and $CA949, respectively (differ-
ence of $CA668), which resulted in an ICER of $CA23,720/
QALY. From a societal perspective, GXR as an adjunctive
therapy to long-acting stimulants and long-acting stimulant
monotherapy were associated with total costs of $CA3,915
and $CA3,582, respectively (difference of $CA334), which
resulted in an ICER of $CA11,845/QALY. In addition, the
incremental response rate at week 8 was 13.5 %, which led
to a NNT at week 8 of 7.41. The incremental cost per
patient-week with response was estimated at $CA102/re-
sponder and at $CA51/responder from a MoH and a soci-
etal perspective, respectively.
Sensitivity analysis
According to the one-way sensitivity analysis results, the
ICER of GXR as an adjunctive therapy to long-acting
stimulants compared to long-acting stimulant monother-
apy varied between $CA14,049/QALY and $CA35,669/
QALY from a MoH perspective. The parameters with the
greatest impact on base-case ICERs from the MoH per-
spective were (i) the calculation of transition probabilities
based on trial data for the first 8 weeks and then LOCF
for the remainder of the study period and (ii) the initial
health state distribution assuming 100 % of patients
started in the severe state (Fig. 2). From a societal perspec-
tive, results of the one-way sensitivity analyses showed
that GXR as an adjunctive therapy to a long-acting stimu-
lant was a dominant alternative compared to long-acting
stimulant monotherapy when (i) 100 % of patients were
assumed to start in the severe state and (ii) productivity
losses of the moderate health state were assumed to be
equivalent to that of the severe health state. In a sensitivity
analysis where patients were maintained on treatment and
could transition between heath states during the weeks 9-
52 period the ICERs increased to $47,909 and $36,034
from a MoH and a societal perspective respectively. Ac-
cording to a willingness to pay threshold of $CA50,000/
QALY, GXR as an adjunctive therapy to long-acting stim-
ulants was a cost-effective alternative over long-acting
stimulant as monotherapy in 100.0 % of the Monte Carlo
simulations, from both MoH and societal perspectives
(Fig. 3).
Discussion
This economic evaluation indicates that, compared to long-
acting stimulants as monotherapy, GXR as an adjunctive
therapy to long-acting stimulants is a cost-effective alterna-
tive among children with ADHD with a suboptimal re-
sponse to stimulants. Results of comprehensive sensitivity
analyses confirm the robustness of the base-case results.
This is the first Canadian economic evaluation of GXR
as an adjunctive therapy in the treatment of ADHD. The
results of a previous CEA performed from a US third-
party payer perspective suggested that GXR as an adjunct-
ive therapy to long-acting stimulants in the treatment of
children and adolescents with ADHD who had a subopti-
mal response to stimulants was cost-effective according to
a willingness to pay threshold of $US50,000/QALY, with
an ICER of $US31,660/QALY [17]. The present economic
evaluation is a Canadian adaptation of the US study pub-
lished by Sikirica et al. [17]. In the US study, the estimated
ICER was higher than that calculated for the Canadian
adaptation ($CA23,720/QALY from a MoH perspective).
Table 3 Cost-effectiveness results – base-case analysis
Long-acting stimulant monotherapy GXR + long-acting stimulant Incrementala
Average QALYs 0.627 0.655 0.028
Patient-weeks with response 12.46 19.03 6.57
Drug costs, $CA 337 1,072 735
Medical costs, $CA 612 545 −67
Productivity losses, $CA 2,633 2,299 −334
Total cost, $CA MoH perspective 949 1,617 668
Total cost, $CA Societal perspective 3,582 3,915 334
Incremental cost/QALY, $CA MoH perspective $CA23,720/ QALY
Incremental cost/QALY, $CA Societal perspective $CA11,845/QALY
Incremental cost/patient-week with response, $CA
MoH perspective
$CA102/responder
Incremental cost/patient-week with response, $CA
Societal perspective
$CA51/responder
aMay not sum to total because of rounding
GXR guanfacine extended release, MoH Ministry of Health, QALY quality-adjusted life year
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These differences could be explained by the higher treat-
ment cost of GXR in the US study and the higher weekly
medical costs. Nevertheless, the findings of both studies
were similar and thus strengthen the conclusion that GXR
as an adjunctive therapy to long-acting stimulants is a
cost-effective alternative compared to long-acting stimu-
lants as monotherapy.
This economic evaluation has several strengths. First,
the model provides results in terms of cost per responder,
which gives further evidence on the cost-effectiveness of
GXR as an adjunctive therapy to a long-acting stimulant
in the treatment of children with ADHD. Moreover, the
analysis accounted for AEs associated with treatments as
well as productivity losses associated with disease severity,
thus allowing a broader perspective and perhaps a more
representative assessment of all the impacts of the disease
and intervention. Lastly, the comparison of GXR as an
adjunctive therapy to short/intermediate-acting stimulants
with short/intermediate-acting stimulants alone allowed
considering the fact that a significant proportion of pa-
tients with ADHD in Canada may receive short/inter-
mediate-acting stimulants because of the reimbursement
criteria and specific conditions required by Canadian
provinces for the coverage of long-acting stimulants [32].
However, this economic evaluation also has some limi-
tations. The difference in number of QALYs between the
two treatments is small, but the difference in number of
patient-weeks with response also indicates a gain in effi-
cacy with the adjunctive therapy. As for any model-based
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Fig. 2 Results of one-way sensitivity analysis. Results of one-way sensitivity analysis are presented in a Tornado diagram from a Ministry of Health
perspective. Lower and upper bounds for considered for the sensibility analysis are indicated on the y-axis for each parameter. The base-case
icremental cost-effectiveness ratio is $CA23,720/QALY. AE: adverse event; CI: confidence interval; ICER: incremental cost-effectiveness ratio; LOCF:
last observation carried forward; MAS-XR: amphetamine mixed salts; MPH-CR: methylphenidate HCl controlled release; QALY: quality-adjusted
life year
Fig. 3 Results of probabilistic sensitivity analysis. Results of probabilistic sensitivity analysis are presented in cost-acceptability curves. Dashed line
is from a MoH perspective while solid line is from a societal perspective. The commonly cited threshold in Canada is $CA50,000/QALY. ICER:
incremental cost-effectiveness ratio; MoH: Ministry of Health; QALY: quality-adjusted life year
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that may increase the uncertainty of the results. First,
although the two-stage model was consistent with an ap-
proach used in a health technology assessment conducted
by the National Institute for Health and Care Excellence,
it was assumed that patients discontinued their treatment
if they transitioned into a moderate or a severe state dur-
ing the second stage of the simulation (weeks 9–52) [22].
Although this may not always be observed in clinical prac-
tice, the latter assumption may be realistic because most
patients are considered to achieve optimal dosing within
the first 8 weeks of treatment and because a significant
proportion of patients discontinue their medication by the
end of 1 year anyway [34, 35]. Furthermore, it was
assumed that patients who discontinued treatment did
not receive subsequent therapy. Although this may not be
representative of the real-world clinical setting, there was
insufficient clinical evidence or consensus in treatment
guidelines on the management of patients who were non-
responsive to adjunctive therapy. Another limitation of the
current study involves the availability of data regarding cost
parameters. As medical costs and productivity losses associ-
ated with disease severity have not been reported, some as-
sumptions were made based on existing studies in order to
estimate these parameters. Although costs associated with
productivity losses usually represent the main cost compo-
nent specific to a societal perspective, other costs, such as
“out-of-pocket” expenses can be also considered with a so-
cietal perspective. In this study, only the addition of costs
associated with productivity losses was considered for the
societal perspective. Moreover, cost of long-acting stimu-
lants was based on daily dose and number of pills according
to Canadian data for children aged 0–12 years, and there-
fore, specific data for patients aged 6–12 years, which cor-
responded to the target population in the study, were not
available. However, patients aged less than 6 years would be
on much lower doses in general. As lower doses used by
very young children may contribute to lower the mean daily
cost of comparators, this would potentially be a conserva-
tive assumption. Similarly, because the OCCI Costing Ana-
lysis Tool divided age into three categories (0–17, 18–69
and 70+ years), some cost parameters associated with
health care resource utilization did not precisely reflect
costs specific for the target age of the population in the
present study. Despite these limitations, findings of this
cost-utility analysis are robust according to the base-case
and confirmed by the robust one-way and probabilistic
sensitivity analyses. Lastly, one other limitation should be
mentioned. As the Wilens et al. study was designed and
powered collectively for only those long-acting stimulants
described previously, future research may need to study
whether there are differences in efficacy among the individ-
ual long-acting medications combinations when GXR was
added to them, or those medications that are on the market
within Canada but were not in the US clinical trial.
Conclusion
This economic evaluation suggests that, from both a soci-
etal and a Canadian health care system perspective, GXR
as an adjunctive therapy to long-acting stimulants is a
cost-effective strategy compared to long-acting stimulant
monotherapy in the treatment of children with ADHD.
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